CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

AbbVie Q3 EPS rises to $2.37; Q3 net revenues climb 10% to $17.4 billion

By Public Technologies
  • AbbVie’s third-quarter GAAP diluted earnings per share rose to $2.37 from a year earlier.
  • Net revenues climbed 10% to $17.4 billion.
  • Immunology net revenues increased 16% to $9.17 billion, while neuroscience net revenues advanced 19% to $3.39 billion.
  • The acquisition of Apogee Therapeutics was completed, expanding the immunology pipeline.
  • The quarterly cash dividend will rise 5% to $1.82 per share, beginning with the payment payable February 16, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG85147) on October 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.